Filing Flows

Filing Flows › 8-K events › Protagenic Therapeutics, Inc.\new

Protagenic Therapeutics, Inc.\new: entry into a material definitive agreement

Form 8-K filed Nov 6, 2026 · items 1.01, 2.03

What the filing says

On November 4, 2026, Protagenic Therapeutics, Inc. (the “Company” or the “Borrower”) issued a promissory note (the “Note”) to Patness LLC (the “Lender”), pursuant to which the Borrower agreed to pay to the order of the Lender the principal sum of $250,000 (the “Principal”). The Note bears simple interest at a rate equa

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Other recent debt and financing

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.